Li Wei, Xu Xiao-Li, Zhang Jun, Cai Jia-Hui, Tang Yun-Xian
Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, Hangzhou, Zhejiang 310006, P.R. China.
Oncol Lett. 2012 Dec;4(6):1269-1273. doi: 10.3892/ol.2012.929. Epub 2012 Sep 20.
The present study was designed to investigate whether cyclooxygenase (COX) inhibitors (coxibs) could prolong survival time by attenuating the tumor growth of ovarian cancer xenograft-bearing mice. Tumor growth and survival time were observed and compared in mice which were treated with a COX-1 inhibitor (SC-560) and a COX-2 inhibitor (celecoxib) every other day for a 21 day period from the day of tumor formation. The trial lasted a total of 121 days. The combination therapy resulted in statistically significant inhibition of tumor size compared with the control group (P<0.05). Additionally, single treatment of SC-560 or celecoxib significantly prolonged the mean survival time of mice compared with the control group (P<0.05). We suggest that COX-1 and COX-2 inhibitors may improve survival and inhibit tumor growth, and that the tumor growth inhibition by coxibs may be the contributing factor for the prolonged survival time in mouse xenograft models.
本研究旨在探讨环氧化酶（COX）抑制剂（coxibs）是否可通过减弱荷卵巢癌异种移植小鼠的肿瘤生长来延长生存时间。从肿瘤形成之日起，每隔一天用COX-1抑制剂（SC-560）和COX-2抑制剂（塞来昔布）对小鼠进行治疗，持续21天，观察并比较小鼠的肿瘤生长和生存时间。试验共持续121天。与对照组相比，联合治疗对肿瘤大小的抑制具有统计学意义（P<0.05）。此外，与对照组相比，单独使用SC-560或塞来昔布可显著延长小鼠的平均生存时间（P<0.05）。我们认为，COX-1和COX-2抑制剂可能改善生存并抑制肿瘤生长，且coxibs对肿瘤生长的抑制可能是小鼠异种移植模型中生存时间延长的促成因素。
